Web-based lifestyle counseling designed to improve adherence to self-management behaviors for diet, exercise, and medication has been shown to reduce blood pressure (BP).
However, the long-term clinical outcome of these interventions is not established. Our aim is to establish whether an e-counseling program is independently associated with improved clinical outcomes over a 12-month period, as defined by the following criteria: i) reduction of systolic BP, diastolic BP, pulse pressure and associated risk factors for cardiovascular events; and ii) adherence to self-management behavior (diet, exercise, smoke-free living and prescribed medication).
Methods and analysis:
REACH is a 2-parallel group, double-blind randomized controlled trial that will utilize a 2 (Groups: e-Counseling vs. Control) by 3 (Assessment intervals: baseline, 4-, and 12-month outcome) design. Blood pressure, lipoprotein cholesterol, physical activity and dietary behaviors and psychological distress will be measured at each assessment. We plan to recruit 528 participants (35 to 74 years of age) diagnosed with stage 1 or 2 hypertension (Systolic BP, 140-180 mmHg; Diastolic BP 90-110 mmHg) from 3 major cities (Toronto, London, Vancouver) and one rural area (Grey Bruce region) across Canada between February 2012 and July 2015. Controls will receive general educational e-messages on heart healthy living and the e-Counseling group will receive tailored e-messages that are matched to their stage of readiness for change. For both groups, e-messages will be sent proactively on a weekly basis during months 1 to 4, then bi-weekly during months 5 to 8, and then monthly during months 9 to 12. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This will be one of the first studies to evaluate the long-term efficacy of preventive ecounseling strategies for cardiovascular disease prevention in patients with hypertension.
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Article focus
• This article describes the study protocol of a multi-centered double-blind randomized controlled trial evaluating the effectiveness of a 12-month lifestyle e-counseling program in reducing risk factors for cardiovascular disease and improving adherence to self-management behaviours in patients with hypertension.
Key messages
• An e-counseling strategy is becoming increasingly prominent in the development of community-based initiatives for cardiovascular disease prevention.
• The long-term clinical outcome of these interventions is not established.
• REACH will be one of the first studies to evaluate the long-term efficacy of preventive e-counseling for cardiovascular disease prevention in patients with hypertension, and findings from this study will be used to guide the ongoing development of e-counseling services at the Heart and Stroke Foundation of Canada.
Strengths and limitations of this study
• A key strength of this trial is that the intervention is grounded in a clinical applied theory of behavior change. Also, an unbiased response by subjects to the REACH protocol will be facilitated by frequent and sustained e-messages that are supportive to both Controls and the Intervention group.
• A limitation of REACH is that any supplementary heart health program in which subjects are enrolled during the REACH trial is only controlled statistically, not 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 ] This is a concern as the risk of cardiovascular mortality among adults 40-69 years of age rises with elevated blood pressure (BP), doubling with each increase of 20 mmHg systolic or 10 mmHg diastolic, from the base index of 115/75 mmHg. [4] Best practice guidelines in North America [5 6] and Europe [7] advocate the strategy of combining pharmacotherapy with lifestyle counseling for patients diagnosed with hypertension and/or who are at elevated risk for CVD. Meta-analyses indicate that programs aimed at improving self-management behaviors significantly decrease systolic BP by 3.0 to 8.7 mmHg relative to Controls. [8] [9] [10] A major challenge for a community-based CVD prevention strategy is to extend the reach of therapeutic lifestyle counseling to individuals with hypertension and/or high CVD risk without overtaxing patient care resources.
Currently, 73% of the Canadian population reports personal access to the internet, which includes 61-69% of Canadians in the 2 lowest income quartiles, and 61% of older Canadians (aged 55 to 64 years). [11] The use of e-based programs that are designed to improve selfmanagement behaviors for diet, exercise, smoke-free living and medication adherence may be well-suited to meet this challenge. Our previous trials of COHRT [12] and I-START [13] have shown that it is feasible to apply an evidence-based model of behavioral counseling with motivational interviewing [14] to a telehealth or e-based program in order to achieve a reduction in systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse pressure (PP). This was achieved by means of increased adherence to self-reported diet and exercise, and it was independent of the therapeutic benefit of medications. However, it is not established whether e-counseling improves clinical outcome and adherence over a long-term interval of at least 12 months.
Thus, the aim of the REACH trial is to establish whether an e-counseling program is independently associated with improved clinical outcomes over a 12-month period, as defined by the following criteria: i) reduction of blood pressure and associated risk factors for cardiovascular events; and ii) adherence to self-management behavior for diet, exercise, smoke-free living and prescribed medication.
Our primary hypotheses are that e-Counseling (vs. Control) will significantly reduce (i) SBP, DBP and PP at the 4-and 12-month assessment intervals, as measured by a validated protocol for automated BP assessment in the clinic; and ii) lipoprotein cholesterol (total, lowdensity, and total/high-density ratio) and the Framingham index of 10-year absolute risk for CVD.
Our secondary hypotheses are that e-Counseling (vs. Control) will significantly increase adherence to self-management behaviors at the 4-and 12-month outcomes, as measured by the following objective and validated indices: mean 4-day step count recorded by a triaxial pedometer, dietary sodium ≤ 100 mmol/day measured by 24-hour urinary sodium, smoke- among subjects who are prescribed antihypertensive medications at baseline.
METHODS

Study Design
REACH is a 2-parallel group, double blind randomized controlled trial that will utilize a 2 (Groups: e-Counseling vs. Control) by 3 (Assessment intervals: baseline, 4-, and 12-month outcome) design. Randomization will be blocked within each of our 4 recruitment sites (Toronto, London, Grey Bruce region, and Vancouver) to ensure overall balance (1:1) in the number of subjects assigned to the 2 groups. This trial will be double blind according to CONSORT standards. [15] The e-Counseling and Control groups will be informed that they will receive e-messages "...that are designed to support a heart healthy lifestyle which is an essential component of blood pressure management." Therefore all subjects will be unaware of whether their intervention is the "experimental" treatment. A randomization code will be embedded into each subject ID number which is known only to the Research Coordinator and Principal Investigators, but not to the research assistants who administer the assessments.
Blinding will be maintained during all assessment sessions (baseline, 4-, and 12-month intervals) and during the data processing and analysis of clinical outcomes. Moreover, subjects will be instructed to not discuss their e-based treatment during these assessments. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Over the 12-month intervention 28 to 30 e-based messages (dependent on # weeks/month) will be sent to Controls and e-Counseling subjects-see Table 1 . E-messages will be send on a weekly basis during months 1 to 4, then bi-weekly between months 5 to 8, and then monthly between months 9 to 12 ( Figure 1 ).
Inclusion/exclusion criteria.
Subjects will be 35 to 74 years of age and diagnosed with stage 1 or 2 hypertension (SBP, 140-180 mmHg; DBP 90-110 mmHg). Among subjects not prescribed medication, hypertension status will be confirmed at baseline by a medical doctor or a nurse practitioner.
Subjects prescribed antihypertensive drugs will be required to have the prescription unchanged for at least 2 months before enrolment. In order to prevent "floor effects" for the analysis of primary outcomes, subjects prescribed antihypertensive medications will also be required to have a baseline blood pressure that is at least in the high normal range (SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg). Exclusion will be based on diagnosis of sleep apnea, kidney disease, major psychiatric illness (eg. psychosis), alcohol or drug dependence in the previous year; pregnancy, institutional residence, or an inability to comprehend English.
Experimental vs. Control Interventions.
Control: An ethical imperative for any long-term trial of preventive e-counseling for hypertension is to ensure that the Control arm receives essential information about preventive guidelines for blood pressure management. From a methodological perspective, it is a priority to balance e-based support across the Control and Experimental arms of the trial to ensure that potential improvement in clinical outcome is not confounded by differences in nonspecific support and attention. Therefore, Controls will be supported with educational eCounseling: Subjects will receive e-messages that will guide them in self-assessing their current stage of motivational readiness for adhering to self-management behaviors as a daily lifestyle routine. These subjects will be directed to select their behavior change priority according to recommended goals for exercise, diet, smoke-free living, and adherence to prescribed antihypertensive medications. In keeping with guidelines from motivational interviewing, subjects will be sent an e-counseling message that is tailored to their selfreported stage of readiness for change. Each message will provide a link to the e-Counseling program on the Heart and Stroke Foundation website. A menu of stage-appropriate eresources for lifestyle change will be presented which will include brief video-taped counseling messages that are matched to each subject's presenting stage of readiness for change. This feedback will be supplemented by online self-monitoring charts and e-handouts that provide guidelines/tips for initiating or maintaining lifestyle change. The content of each video-taped message will be consistent with clinical guidelines for motivational interviewing, [14] as established in our previously adapted manual. [16] Accordingly, the video clips will highlight key clinical features that are applicable to our targeted selfmanagement behaviors, and which promote the following: validation of the subject's presenting stage of readiness for behavior change, individual review of salient pro's vs. con's for change that determine decisional balance, resolution of ambivalence for change, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 for relapse prevention to maintain adherence.
Recruitment and Randomization
We will replicate the successful recruitment strategy from our previous trial (I-START) [13] by Randomization will be conducted by a computer program (randomize.net) using randomly permuted blocks to assign subjects to Control or e-Counseling. Randomization code will be hidden from research assistants during assessments and data processing of the primary and secondary outcomes. An unbiased response by subjects to the REACH protocols will be facilitated by frequent and sustained e-messages (Table 1) that are likely to be perceived as being supportive in nature. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Baseline, 4-and 12-month assessments in REACH will be scheduled between 8:00 a.m. and 12:00 p.m to minimize diurnal BP variability. Subjects will be instructed to fast for 12 hours in order to obtain a valid profile of lipoprotein cholesterol. They will also be directed to refrain from smoking for at least 4 hours, caffeine for 12 hours, and strenuous exercise for 24 hours prior to their appointment. Anthropometric characteristics, medical history and medication information will be collected. Medication adherence will be calculated by the Medication Possession Ratio which is defined as the quantity of antihypertensive medication that has been utilized over each 4-month interval vs. the quantity that has been prescribed, based upon pharmacy refill data. [17] Resting blood pressure, physical activity, dietary behavior, psychological distress, and subject's readiness to change will be examined at each assessment interval. Feedback of the Framingham 10-year absolute risk for CVD will be provided to the subjects at the end of each assessment.
Assessment Protocol
Blood pressure: Primary outcome measures of SBP, DBP and PP will be assessed by a validated protocol for automated BP assessments using the BpTRU device. Subjects will be seated for at least 5 minutes prior to activation of BpTRU. The BP cuff will be applied to the left arm of the subject by a nurse or trained research assistant. An initial BP measurement will be recorded. The nurse/research assistant will then exit the room while the BpTRU device completes an automated series of 5 BP recordings. A 1-minute interval will separate each of these recordings. The recorded blood pressure (SBP, DBP, PP) at each assessment interval will be the mean of these 5 BpTRU measurements. 
Salivary cotinine:
Physiologic evaluation of smoking status will be recorded by salivary cotinine among subjects who are current smokers at baseline. Positive exposure to nicotine that is consistent with smoking will be defined by cotinine ≥ 10 ng/ml. This evaluation will screen for exposure to nicotine replacement therapy, which would confound the interpretation of the cotinine index.
Readiness for change:
Prochaska's Transtheoretical algorithm will be used to operationally define motivational readiness to initiate or maintain self-management behaviors that include planned exercise, daily activities for active living, fruit and vegetable intake, salt use, alcohol consumption, and smoke-free living. The stages of change is conventionally defined as 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Sample Size
The sample size estimation was based on the meta-analysis by Neubeck et al. [26] who evaluated the efficacy of randomized controlled trials of preventive telehealth and e-based programs in modifying blood pressure: weighted mean difference in SBP between experimental vs. control groups = -4.69 mm Hg, common pooled variance = 354, pooled SD = 18.81. In order to replicate this outcome, the estimated sample = 254 subjects per group (using a 2-parallel group design, type 1 error = 5% and power = 80%). Dropouts from this study will be interpreted as an intervention failure. Therefore, we will recruit a sample of 528 subjects. 15 Linear Mixed Models with a random effects intercept will be used to evaluate whether within-subject change across assessment intervals is independently and significantly associated with the e-Counseling group, for each primary and secondary outcome. [27] Generalized estimation equations for repeated measures will be used to analyze categorical outcomes (e.g. smoking cessation status). All significant interactions or main effects in our statistical models will be followed up with post-hoc contrasts, using a Bonferroni correction for the statistical significance criterion of p < 0.05.
Statistical Analysis
ETHICS AND DISSEMINATION
All participants will be provided written informed consent. The study protocol, consent forms and questionnaires were approved by the research ethics boards at the University Health Network, University of British Columbia, London Health Sciences Center and the Grey Bruce Public Health Unit. Ethics approval will be renewed on an annual basis.
Meta-analytic evidence clearly supports the use of lifestyle counseling to reduce SBP and risk for premature mortality. Programs aimed at improving self-management behaviors significantly decrease SBP by 3.0 to 8.7 mmHg relative to Controls. [8] [9] [10] In order to optimize the efficacy of lifestyle change interventions it is essential to develop strategies to sustain long-term adherence to recommended self-management behaviors.
It is likely that a preventive e-counseling strategy will become increasingly prominent in the development of community-based initiatives for CVD prevention, once the long-term efficacy of this approach is established. This point is highlighted by evidence that there is 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In sum, we anticipate that findings from the REACH trial will have high population impact, given our collaboration with the Heart and Stroke Foundation of Canada. Advancements achieved with this trial, concerning the content and methodology of preventive e-counseling, will be widely disseminated to the general public and likely utilized in follow-up research by our team and others. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
CONFLICT OF INTEREST
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Results
Participant flow (a diagram is strongly recommended)
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome n/a 13b For each group, losses and exclusions after randomisation, together with reasons n/a Recruitment 14a Dates defining the periods of recruitment and follow-up n/a 14b Why the trial ended or was stopped n/a Baseline data 15 A 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 
